Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Oyster Point Pharma Inc (NQ: OYST )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 30, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Oyster Point Pharma Inc

< Previous 1 2 3 Next >
Health Care Becomes Most Overweighted Sector As Hedge Funds Crowd Into Magnificent 7
Goldman Sachs' Hedge Fund Trend Monitor highlights concentration in mega-caps, with optimism in AI and health care. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
The 7 Best Crypto and Stocks to Buy as Christmas Gifts This Year
These stocks to buy as Christmas gifts provide a number of reasons for investors to rejoice this holiday season. 
Via InvestorPlace
The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond
These seven hottest healthcare stocks have strong growth catalysts that could send each of them higher over the next few years. 
Via InvestorPlace
OYSTER POINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Oyster Point Pharma, Inc. - OYST
From Kahn Swick & Foti, LLC
Via Business Wire
Why Viatris Stock Is Jumping Today
Investors are applauding a key step in Viatris' plans to return to growth. 
Via The Motley Fool
Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Oyster Point Pharma, Inc.
Via GlobeNewswire
Better Dividend Stock: AbbVie or Viatris?
These pharmaceutical companies are profitable and offer above-average dividends. 
Via The Motley Fool
Oyster Point Pharma Reports Third Quarter 2022 Financial Results and Recent Business Highlights
From Oyster Point Pharma, Inc.
Via GlobeNewswire
OYSTER POINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Oyster Point Pharma, Inc. - OYST
From Kahn Swick & Foti, LLC
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Oyster Point Pharma, Inc. (Nasdaq - OYST), Benefitfocus, Inc. (Nasdaq - BNFT), Abiomed, Inc. (Nasdaq - ABMD), Atlas Corp. (NYSE - ATCO)
From Brodsky & Smith LLC
Via GlobeNewswire
Cigna To $335? Plus This Analyst Slashes PT On Six Flags Entertainment By 25%
  SVB Leerink raised the price target on Cigna Corporation (NYSE: CI) from $305 to $335. Cigna shares rose 0.7% to close at $324.37 on Monday. 
Via Benzinga
Spirit AeroSystems, Oyster Point Pharma, Snap And Other Big Gainers From Monday
U.S. stocks closed higher on Monday, with the Dow Jones surging more than 400 points. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2022
Upgrades 
Via Benzinga
Dow Surges 400 Points; Crude Oil Down 1%
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 400 points on Monday. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers 
Via Benzinga
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Analyzing Oyster Point Pharma's Short Interest
Oyster Point Pharma's (NASDAQ:OYST) short percent of float has fallen 17.95% since its last report. The company recently reported that it has 1.69 million shares sold short, which is 11.93% of all... 
Via Benzinga
Why Oyster Point Pharma Shares Are Trading Higher By Around 40%? Here Are 49 Stocks Moving In Monday's Mid-Day Session
Gainers Dragon Victory International Limited (NASDAQ: LYL) surged 52.2% to $0.6870. 
Via Benzinga
Dow Jumps Over 200 Points; Verve Therapeutics Shares Plummet
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 200 points on Monday. 
Via Benzinga
Oyster Point Pharma (NASDAQ: OYST) Enters Into Agreement to be Acquired by Viatris (NASDAQ: VTRS) For $11 Per Share Plus CVR Up to $2.00 Per Share
Oyster Point Pharma, Inc. (NASDAQ: OYST) is engaged as a commercial-stage biopharmaceutical company, which is focused on the research, development 
Via Spotlight Growth
Viatris Bolsters Its Ophthalmology Franchise With Oyster Point Pharma Deal, Shares Surge
Via Benzinga
Viatris (VTRS) Stock Pops 17% on Acquisition News
One press release with numerous positive catalysts is prompting some VTRS stock traders to load up on the shares today. 
Via InvestorPlace
US Stocks Mixed; Dow Rises Over 50 Points
U.S. stocks traded mixed this morning, with the Dow Jones gaining over 50 points on Monday. 
Via Benzinga
OYST Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Oyster Point Pharma, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Oyster Point Pharma, a Leading Ophthalmology-Focused Biopharmaceutical Company, to be Acquired by Viatris
From Oyster Point Pharma, Inc.
Via GlobeNewswire
Oyster Point Pharma To Report Third Quarter 2022 Financial Results On November 10, 2022
Conference Call and Webcast Scheduled for November 10, 2022, 4:30 p.m. ET 
From Oyster Point Pharma, Inc.
Via GlobeNewswire
Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Oyster Point Pharma, Inc.
Via GlobeNewswire
Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Oyster Point Pharma, Inc.
Via GlobeNewswire
10 Short Squeeze Candidates That May Soar: Minerva Neurosciences, FaZe, Getty Images And More
Potential short squeeze plays gained steam in 2021 and have continued through 2022 with new traders looking for the next huge move. 
Via Benzinga
This Nasal Spray For Eye Disease Stock Is 'Attractive', Has Potential 160% Upside
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.